Natural killer cells and anti-tumor immunity.


Journal

Molecular immunology
ISSN: 1872-9142
Titre abrégé: Mol Immunol
Pays: England
ID NLM: 7905289

Informations de publication

Date de publication:
06 2019
Historique:
received: 29 07 2017
revised: 20 11 2017
accepted: 01 12 2017
pubmed: 14 12 2017
medline: 29 10 2019
entrez: 14 12 2017
Statut: ppublish

Résumé

Immune checkpoint inhibitors harness the power of the immune system to fight cancer. The clinical success achieved with antibodies against the inhibitory T cell receptors PD-1 and CTLA4 has focused attention on the possibility of manipulating other immune cells, in particular those involved in innate immunity. Here we review the role of innate lymphoid cells (ILCs) and their contribution to tumor immunity. As the prototypical ILC, the natural killer (NK) cell has an intrinsic ability to detect and kill cancer cells. NK cells are dependent on the cytokine interleukin (IL)-15 for their development and effector activity. We discuss the role of the Suppressor of cytokine (SOCS) proteins in negatively regulating IL-15 and NK cell responses and the potential for targeting these small intracellular regulators as new immune checkpoints.

Identifiants

pubmed: 29233542
pii: S0161-5890(17)30595-3
doi: 10.1016/j.molimm.2017.12.002
pii:
doi:

Substances chimiques

Suppressor of Cytokine Signaling Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

40-47

Informations de copyright

Copyright © 2017 Elsevier Ltd. All rights reserved.

Auteurs

Sandra E Nicholson (SE)

Walter and Eliza Hall Institute of Medical Research, Melbourne, 3052, Australia; and Department of Medical Biology, University of Melbourne, Melbourne, 3010, Australia. Electronic address: snicholson@wehi.edu.au.

Narelle Keating (N)

Walter and Eliza Hall Institute of Medical Research, Melbourne, 3052, Australia; and Department of Medical Biology, University of Melbourne, Melbourne, 3010, Australia.

Gabrielle T Belz (GT)

Walter and Eliza Hall Institute of Medical Research, Melbourne, 3052, Australia; and Department of Medical Biology, University of Melbourne, Melbourne, 3010, Australia. Electronic address: belz@wehi.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH